BDX
$26M—
Bcal Diagnostics
Diagnostics · Oncology
Developing a simple blood test for early breast cancer detection using calcium-binding biomarkers.
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$2.4M
Mar 2026 4C
Runway
—Based on Mar 2026 4C
Market Cap
$26M
Burn Rate
—
Mar 2026 4C
Shares Outstanding
369M
Pipeline Assets
1
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther19 May 2026
BCAL Launches Early Detection Cancer Platform
BCAL has launched a comprehensive commercialisation infrastructure for early cancer detection tests, including integration into 97% of Australian GP software systems, a telehealth platform (EarlyDetection.com.au), and a Sydney clinic. The multi-cancer early detection test is expected in June 2026, with the pancreatic market alone representing >A$250M per annum opportunity.
3M Price
BDX.ASX$0.070-39.1% 3M
Low $0.070High $0.115
Pipeline Assets (1)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
3 transactionsLast 90dNet Buy
Buys3+3 vs prior
Sells0
Buy Value$60k
Catalysts (4)· 2 upcoming · 2 past
Enhanced BREASTESTplus launch (C+D density)
UpcomingConfirmedarrow_upwardHigh30 June 2026
Expectedarrow_upwardHigh30 June 2026
Related activity
19 May 2026 · BCAL Launches Early Detection Cancer PlatformTrack RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
2/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 4 tracked
Filed 1 of 1 4Cs on time· statutory deadline
Completed catalysts
✓BCAL Appoints Anne-Louise Arnett as Chief Executive Officer— BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective 1 June 2026, bringing 25+ years of medical technology commercialisation experience to accelerate the company's commercial roadmap and international expansion. Outgoing CEO Shane Ryan transitions to Director Clinical Affairs Breast Cancer to ensure continuity, while Executive Chair Jayne Shaw moves to Non-Executive Chair role on 1 July 2026.
On time
✓BCAL Launches Early Detection Cancer Platform— BCAL has launched a comprehensive commercialisation infrastructure for early cancer detection tests, including integration into 97% of Australian GP software systems, a telehealth platform (EarlyDetection.com.au), and a Sydney clinic. The multi-cancer early detection test is expected in June 2026, with the pancreatic market alone representing >A$250M per annum opportunity.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Announcements(9)
article
OtherPSauto_awesome
BCAL Appoints Anne-Louise Arnett as Chief Executive Officer10 May 2026
expand_more318KB